Cytiva

Accelerate critical drug discovery decisions, without compromising on data quality. As drug discovery becomes more complex, scientists need faster insights without sacrificing data confidence. The next-generation Biacore 8S and 8S+ systems bring rapid screening and high-quality molecular characterization together in a single automated platform. Read more: https://okt.to/ENMyPe

What if every decision showed not just the price tag, but the emissions behind it? When carbon is visible, behavior changes. And for Thibault Renaud transparency is where real decarbonization begins. That’s why conversations like Sustainability Live: the NetZero Summit matter, they move net zero from ambition to action. What are we doing about it? https://okt.to/OFmIJ1

The biopharma supply chain was not designed for today’s world. Tariffs, regionalization, regulatory divergence. All happening at once. Our 2025 Global Biopharma Index shows that 76 percent of leaders expect trade barriers to materially change how they source in the year ahead. The old playbook, optimized for cost and efficiency, is no longer enough. Resilience now depends on collaboration that goes beyond traditional vendor relationships. In this article, John Clarke explores what supply chain collaboration really needs to look like in a fragmented world, and why standing still carries its own risk. 🔗 https://okt.to/apnmz4

ELEVECTA™ transient cell line for AAV manufacturing has received the FDA’s Advanced Manufacturing Technology (AMT) designation – recognizing innovations that raise the bar for reliability, efficiency, and quality in advanced therapies. What this means for drug developers: - Earlier, more structured FDA engagement from the start - Streamlined CMC pathways that reduce regulatory friction - Greater planning confidence to stay focused on getting therapies to patients ELEVECTA™ transient cell line is engineered to minimize encapsidated host cell DNA – consistently meeting FDA and WHO expectations and establishing a stronger quality baseline from day one. A clearer path to clinic starts here. Learn more about ELEVECTA™ transient and what the AMT designation means for your program. Read the press release. https://okt.to/60YOsv

ASGCT conversations are shifting: less ‘what’s possible?’ and more ‘what’s scalable?’ Swipe to see the sessions where our scientists are contributing to the conversation 👇 🔬 Democratizing Gene Therapy: Upstream Innovations to Streamline CMC and Reduce Cost per Dose 📅 May 12 | 8:00 AM Emmanuelle Cameau, Scientific Director, Viral Vectors explores how CMC strategy is evolving to support broader access. 🧬 Panel: The risk–reward balance of in vivo CAR T: Are we ready for the next leap in advanced therapies? 📅 May 12 | 12:15 PM A forward-looking discussion on emerging modalities and what they mean for CGT platforms. ⚙️ From workflow to platform: configurable, scalable manufacturing solutions for autologous CAR T and solid tumor applications 📅 May 14 | 4:00 PM Federico Franchi, Senior Manager CT Biology & Applications, and Sree Desphande, Associate Senior Scientist, share how integrated, scalable approaches can unlock progress. 📍 Be sure to connect with the Cytiva team at the Danaher booth, #1337. Let’s talk about moving advanced therapies from promise to practice. #ASGCT2026 #CellTherapy #GeneTherapy #AdvancedTherapies #CGT #CMC #Manufacturing #Cytiva

Bioprocessing rarely makes headlines, but it’s increasingly the constraint that decides whether breakthroughs become therapies people can actually access. A timely POV on the “hidden engine” behind biologics, and what it will take to scale science with confidence. Read here: https://lnkd.in/gRF9BxJm

Happy Friday – prescribing a quick chuckle to end the week😄.

Which shift moves the needle fastest: shared risk over capex, real collaboration in early phase, or small market partnerships that actually happen? Hear the picks from BioOra managing director John Robson, NIBRT National Institute for Bioprocessing Research and Training director John Milne PhD and AGC Biologics Vice President Ben Clauberg. 🎥 Watch, then map your bets with the Global Biopharma Index 👉 https://okt.to/2yVO8U

Meet the growing demand for real‑time decision‑making in biopharma R&D. Biopharma organizations are increasingly turning to real-time data analytics to prioritize and accelerate development as R&D costs and modality complexity rise. As industry pressures intensify, SPR solutions built for quality, flexibility, and scalability are becoming essential to staying competitive. The Biacore 8 series system helps your teams stay ahead of the curve by delivering: ✅Real‑time, high‑quality interaction data to support faster, more confident decisions ✅Outstanding sensitivity to detect subtle binding events that matter early in development ✅A scalable SPR platform that grows with shifting pipeline demands, from screening to in‑depth characterization ✅Robust interaction analysis across diverse and increasingly complex therapeutic modalities Explore real‑time insights with SPR designed for today’s needs, and tomorrow’s growth. Discover now https://okt.to/9Kz6mg

Digital transformation in biopharma shouldn’t be reserved for the biggest players. That’s why this matters 👇 Small and mid-sized biopharma companies are under pressure to move faster, from process development to clinical and beyond, yet many are still stuck stitching together disconnected, proprietary systems. The result? Manual workarounds, data silos, and real risk at scale. Rockwell Automation and Cytiva are changing that equation. Read how here. https://okt.to/HlyIW0